Possible predictive value of Maspin expression in colorectal cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 2, 2013, Pages 183-190

  Gurzu, Simona ^a   Szentirmay, Zoltan ^b   Toth, Erika ^b   Jung, Ioan ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Angiogenesis; Colorectal cancer; Maspin; Tumor stage

Indexed keywords

CD31 ANTIGEN; ENDOGLIN; FLUOROURACIL; MASPIN; PROTEIN P53; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STAGING; CELL NUCLEUS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 84875292925     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308020006     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA. Cancer. J Clin 2010; 60: 277-300.
2. Figueredo A, Coombes M E, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; 16: CD005390.
3. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87.
4. Catwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of Bevacizumab beyond progression in metastatic colorectal cancer patients treated in US Community Oncology. Clin Colorectal Cancer 2012; 11(4): 238-46.
5. Volpert, O., Mirochnik, Y. Methods and composition for inhibiting angiogenesis. US8198406 (2012).
6. Qin L, Zhang M. Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J Biol Chem 2010; 285: 32360-9.
7. Li Z, Shi HY, Zhang, M. Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene 2005; 24: 2008-19.
8. Zou Z, Anisowicz A, Hendrix MJC, Thor A, Neveu M, Sheng S, et al. Maspin: A Serpin with tumor suppressing activity in human mammary epithelial cells. Science 1994; 263, 526-9.
9. Neal CL, Henderson V, Smith BN, Mc Keithen D, Graham T, Vo BT, et al. Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer 2012; 12: 336.
10. Endsley MP, Hu Y, Deng Y, He X, Warecjcka DJ, Twining SS, et al. Maspin, the molecular bridge between the plasminogen activator system and α1 Integrin that facilitates cell adhesion. J Biol Chem 2011; 286: 24599-607.
11. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z, Hendrix MJ. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther 2005; 4: 400-6.
12. McGowen R, Biliran H Jr, Sager R, Sheng S. The surface of prostate carcinoma DU145 cells'mediates the inhibition of urokinasetype plasminogen activator by maspin. Cancer Res 2000; 60: 4771-8.
13. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Seftor EA, et al. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2003; 2: 398-403.
14. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 2002; 100: 452-5.
15. Zheng H, Tsuneyama K, Cheng C, Hiroyuki T, Zhengguo C, Murai Y, et al. Maspin expression was involved in colorectal adenomaadenocarcinoma sequence and liver metastasis of tumors. Anticancer Res 2007; 27: 259-66.
16. Yang Y, Shi H, Li X, Yi Y. Effects of shRNA targeting maspin on invasion of gastric carcinoma SCG7901 cell line. Oncol Rep 2011; 25: 259-65.
17. Cao D, Zhang Q, Wu LSF, Salaria SN, Winter JW, Hruban RH, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: Tissue microarray analysis of 223 surgically resected cases. Mod Pathol 2007; 20: 570-8.
18. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749-56.
19. Weber T, Link KH. Multimodal therapy for colon cancer: State of the art. Zentralbl Chir 2011; 136: 325-33.
20. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol 2011; 38: 511-20.
21. Berger, A., Guillemette, T.L., Bryant, B.M., Morrisey, M.P., Schlegel, R. Composition, kits and methods for identification, assessement, prevention, and therapy of colon cancer. US20030148314 (2003).
22. Lee, N.M., Chen, L.C. Biomarkers panel for colorectal cancer. US20050014165 (2005).
23. Watson, D., Paik, S., Cowens, W., Baker, J.B., Clarck, K., Hackett, J. Gene expression markers for colorectal cancer prognosis. US8198024 (2012).
24. Baker, B.J., Cowens, W., Lagone, K., Hackett, J., Watson, D., Paik, S. Gene expression markers for prediction of patient response to chemotherapy. US20120040842 (2012).
25. Shack, S., Watson, D., Li, X., Lee, L., Langone, K. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy. US8067178 (2011).
26. Lee-Hoeflich, S.T., Stern, H. Gene expression markers of tumor resistance to HER2 inhibitor treatment. US20100298156 (2010).
27. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rummele P, Hartmann A, et al. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2005; 118: 2247-54.
28. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Borbeck K, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 2002; 360: 1381-91.
29. Barton, M. p53 modulated and cancer target. US8211635 (2012).
30. Wang, S., Yang, D., Xu, L. Small molecule antagonists of Bcl-2 family proteins. US8163805 (2012).
31. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114: 1188-95.
32. Song SY, Lee SK, Kim DH, Son HE, Kim HJ, Lim YJ, et al. Expression of maspin in colon cancers. Its relationship with p53 expression and microvessel density. Dig Dis Sci 2002; 47: 1831-5.
33. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011; 300: 197-204.
34. Jensen NF, Smith DH, Nygard SB, Romer MU, Nielsen KV, Brunner N. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 2012; 47: 340-55.
35. Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. Beyond bevacizumab: New anti-VEGF startegies in colorectal cancer. Expert Opin Investig Drugs 2012; 21(7): 949-59.
36. Impagnatiello MA, Bianchi E, Di Stefano R, Pardi R, Mosca F. A novel approach to identification of genes involved in neoangiogenesis: Implication for graft re-vascularization. Transplant Proc 1997; 29: 1110.
37. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13.